Voclosporin Clinical Trials (2026): 23 Studies for Lupus Nephritis & Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
23 Voclosporin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Lupus Nephritis & Psoriasis) and 4,042 total planned enrollment. 9 Phase 3 Voclosporin trials and 7 Phase 2, 1 Phase 4 are listed. 3 Voclosporin clinical trials are actively recruiting at 7 U.S. sites across 5 states. Most recent activity: NCT07053891 (Jun 2032).
Where to Participate: All Voclosporin Trial Sites in the U.S. (7 sites across 5 states)
Every actively recruiting Voclosporintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | AARA Clinical Research | Glendale85306 | NCT07225387 | Map |
| GA | Piedmont Physicians Rheumatology | Atlanta30318 | NCT07225387 | Map |
| GA | Georgia Nephrology Research Institute | Lawrenceville30046 | NCT07225387 | Map |
| GA | Parris & Associates | Lawrenceville30046 | NCT07225387 | Map |
| OH | Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center | Columbus43201 | NCT07225387 | Map |
| OK | Oklahoma Medical Research Foundation | Oklahoma City73104 | NCT07225387 | Map |
| TX | AARA Clinical Research | Fort Worth76109 | NCT07225387 | Map |
Voclosporin clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | withdrawn | no longer available | Total |
|---|---|---|---|---|---|---|
| P1 | 3 | 3 | ||||
| P2 | 5 | 2 | 7 | |||
| P2/P3 | 1 | 1 | ||||
| P3 | 1 | 5 | 2 | 1 | 9 | |
| P4 | 1 | 1 | ||||
| N/A | 1 | 1 | 2 |
Recruiting Voclosporin clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07053891 | LUPKYNIS Drug-use Results Survey | — | Lupus Nephritis | 400 | Sep 2025 |
| NCT06406205 | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | P3 | Lupus Nephritis | 270 | Dec 2023 |
| NCT07225387 | SYNERGYSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial | P4 | Lupus Nephritis | 30 | Oct 2024 |
Voclosporin clinical trials by indication
Lupus Nephritis (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07053891 | — | N/A | recruiting | LUPKYNIS Drug-use Results Survey |
| NCT06406205 | — | P3 | recruiting | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis |
| NCT07225387 | SYNERGY | P4 | recruiting | Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial |
| NCT03597464 | AURORA 2 | P3 | completed | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin |
| NCT03021499 | AURORA | P3 | completed | Aurinia Renal Response in Active Lupus With Voclosporin |
| NCT02949973 | AURION | P2 | completed | Aurinia Early Urinary Protein Reduction Predicts Response |
| NCT02141672 | AURA-LV | P2 | completed | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) |
Psoriasis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00408187 | ESSENCE | P3 | completed | Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients |
| NCT00258713 | SPIRIT | P3 | completed | A 36-Week Extension to Protocol ISA04-03 |
| NCT00244842 | SPIRIT | P3 | completed | Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis |
Adolescent Lupus Nephritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05962788 | VOCAL-EXT | P3 | terminated | Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis |
| NCT05288855 | VOCAL | P3 | terminated | Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05306873 | DIVERT | P2 | terminated | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus |
Drug-drug Interaction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05306379 | Statin-DDI | P1 | completed | Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin |
Covid19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04701528 | VOCOVID | P2 | completed | Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients |
Dry Eye Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04147650 | AUDREY | P2/P3 | completed | Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome |
Dry Eye (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03597139 | — | P2 | completed | Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease |
Focal Segmental Glomerulosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03598036 | AURONA™ | P2 | terminated | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis |
Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02949999 | — | P1 | completed | Voclosporin in Healthy Japanese Volunteers |
Renal Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01586845 | INSPIRE | P3 | withdrawn | Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation |
Keratoconjunctivitis Sicca (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00851734 | KCS | P1 | completed | A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) |
Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00270634 | PROMISE | P2 | completed | Study of ISA247 (Voclosporin) in De Novo Renal Transplantation |
Immunosuppression (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01236287 | — | N/A | no longer available | Special Access for the Use of Voclosporin for Kidney Transplantation |
Voclosporin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SYNERGY | NCT07225387 | P4 | recruiting | Lupus Nephritis | 30 | — |
| VOCAL-EXT | NCT05962788 | P3 | terminated | Adolescent Lupus Nephritis | 4 | — |
| VOCAL | NCT05288855 | P3 | terminated | Adolescent Lupus Nephritis | 9 | — |
| AURORA 2 | NCT03597464 | P3 | completed | Lupus Nephritis | 216 | PMID 37528520 |
| AURORA | NCT03021499 | P3 | completed | Lupus Nephritis | 358 | PMID 22087680 |
| INSPIRE | NCT01586845 | P3 | withdrawn | Renal Transplantation | 0 | PMID 21245533 |
| ESSENCE | NCT00408187 | P3 | completed | Psoriasis | 642 | PMID 16488299 |
| SPIRIT | NCT00258713 | P3 | completed | Psoriasis | 309 | — |
| SPIRIT | NCT00244842 | P3 | completed | Psoriasis | 451 | PMID 18424323 |
| DIVERT | NCT05306873 | P2 | terminated | Systemic Lupus Erythematosus | 12 | — |
| VOCOVID | NCT04701528 | P2 | completed | Covid19 | 20 | — |
| AURONA™ | NCT03598036 | P2 | terminated | Focal Segmental Glomerulosclerosis | 5 | PMID 23736966 |
| AURION | NCT02949973 | P2 | completed | Lupus Nephritis | 10 | — |
| AURA-LV | NCT02141672 | P2 | completed | Lupus Nephritis | 265 | PMID 19369404 |
| PROMISE | NCT00270634 | P2 | completed | Kidney Diseases | 334 | PMID 24243422 |
Terminated and withdrawn Voclosporin trials (5)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05962788terminatedLong-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
- NCT05288855terminatedVoclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
- NCT05306873terminatedExamining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
- NCT03598036terminatedDose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
- NCT01586845withdrawnSafety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation
All Voclosporin trials (23)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07053891 | LUPKYNIS Drug-use Results Survey | — | recruiting | 400 | Otsuka Pharmaceutical Co., Ltd. | Sep 2025 | |
| NCT06406205 | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | P3 | recruiting | 270 | Qilu Pharmaceutical Co., Ltd. | Dec 2023 | |
| NCT07225387 | SYNERGY | Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial | P4 | recruiting | 30 | NephroNet, Inc. | Oct 2024 |
| NCT05962788 | VOCAL-EXT | Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis | P3 | terminated | 4 | Aurinia Pharmaceuticals Inc. | Mar 2024 |
| NCT05288855 | VOCAL | Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis | P3 | terminated | 9 | Aurinia Pharmaceuticals Inc. | Oct 2023 |
| NCT05306873 | DIVERT | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus | P2 | terminated | 12 | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 2022 |
| NCT04701528 | VOCOVID | Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients | P2 | completed | 20 | Leiden University Medical Center | Nov 2020 |
| NCT05306379 | Statin-DDI | Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin | P1 | completed | 24 | Aurinia Pharmaceuticals Inc. | Jan 2022 |
| NCT03597464 | AURORA 2 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin | P3 | completed | 216 | Aurinia Pharmaceuticals Inc. | Sep 2019 |
| NCT04147650 | AUDREY | Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome | P2/P3 | completed | 508 | Aurinia Pharmaceuticals Inc. | Oct 2019 |
| NCT03598036 | AURONA™ | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis | P2 | terminated | 5 | Aurinia Pharmaceuticals Inc. | Jun 2018 |
| NCT03021499 | AURORA | Aurinia Renal Response in Active Lupus With Voclosporin | P3 | completed | 358 | Aurinia Pharmaceuticals Inc. | May 2017 |
| NCT03597139 | Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease | P2 | completed | 100 | Aurinia Pharmaceuticals Inc. | Aug 2018 | |
| NCT02949973 | AURION | Aurinia Early Urinary Protein Reduction Predicts Response | P2 | completed | 10 | Aurinia Pharmaceuticals Inc. | Jun 2015 |
| NCT02141672 | AURA-LV | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) | P2 | completed | 265 | Aurinia Pharmaceuticals Inc. | Jun 2014 |
| NCT02949999 | Voclosporin in Healthy Japanese Volunteers | P1 | completed | 40 | Aurinia Pharmaceuticals Inc. | Oct 2016 | |
| NCT01586845 | INSPIRE | Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation | P3 | withdrawn | 0 | Aurinia Pharmaceuticals Inc. | Mar 2013 |
| NCT01236287 | Special Access for the Use of Voclosporin for Kidney Transplantation | — | no longer available | 0 | Weill Medical College of Cornell University | — | |
| NCT00270634 | PROMISE | Study of ISA247 (Voclosporin) in De Novo Renal Transplantation | P2 | completed | 334 | Aurinia Pharmaceuticals Inc. | Jan 2006 |
| NCT00851734 | KCS | A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) | P1 | completed | 35 | Lux Biosciences, Inc. | Feb 2009 |
| NCT00408187 | ESSENCE | Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients | P3 | completed | 642 | Aurinia Pharmaceuticals Inc. | Dec 2006 |
| NCT00258713 | SPIRIT | A 36-Week Extension to Protocol ISA04-03 | P3 | completed | 309 | Aurinia Pharmaceuticals Inc. | Sep 2005 |
| NCT00244842 | SPIRIT | Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis | P3 | completed | 451 | Aurinia Pharmaceuticals Inc. | Dec 2004 |
Voclosporin clinical trials: frequently asked questions
- How many Voclosporin clinical trials are there?
- 23 Voclosporin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 14 are marked completed.
- Are Voclosporin clinical trials recruiting in 2026?
- Yes — 3 Voclosporin trials are actively recruiting in 2026, with 7 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Voclosporin being studied for?
- Voclosporin is being studied for Lupus Nephritis, Psoriasis, Keratoconjunctivitis Sicca, Pediatric Lupus Nephritis, Adolescent Lupus Nephritis and 12 more. The trials are grouped by indication on this page.
- What phase is Voclosporin in?
- Voclosporin clinical trials span 1 Phase 4, 9 Phase 3, 7 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Voclosporin clinical trials?
- The lead sponsor across the most Voclosporin trials is Aurinia Pharmaceuticals Inc., with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Voclosporinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: